- United States
- /
- Personal Products
- /
- NasdaqCM:GHSI
Guardion Health Sciences Second Quarter 2024 Earnings: US$1.66 loss per share (vs US$0.93 loss in 2Q 2023)
Guardion Health Sciences (NASDAQ:GHSI) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$72.9k (down 97% from 2Q 2023).
- Net loss: US$2.13m (loss widened by 82% from 2Q 2023).
- US$1.66 loss per share (further deteriorated from US$0.93 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Guardion Health Sciences shares are down 2.7% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Guardion Health Sciences that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:GHSI
Guardion Health Sciences
A clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally.
Flawless balance sheet and overvalued.